| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/18/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...|
Docs:
|
"SECURITIES SUBSCRIPTION AGREEMENT This SECURITIES SUBSCRIPTION AGREEMENT is made and entered into this 8th day of August, 2023 by and among Novavax, Inc., a Delaware corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 , and SK bioscience Co., Ltd., a company incorporated in the Republic of Korea having a place of business at 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13494, Republic of Korea . The Company and SK shall each be hereinafter referred to as a “Party” and collectively as the “Parties”. WHEREAS, the Company and SK are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended ; and WHEREAS, the Company desires to issue to SK, shares of ..." |
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/11/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 06/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 12.1% stake in AMENDED FILING NOVAVAX INC |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/04/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/14/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/28/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.4% stake in Novavax Inc. |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/28/2022 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Quarterly results |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/19/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/15/2022 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
|